ReviewCancer management and research2022

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.

Karen M Yun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.